Bellevue Group AG Lowers Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Bellevue Group AG reduced its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 36.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,558 shares of the biopharmaceutical company’s stock after selling 15,642 shares during the period. Bellevue Group AG’s holdings in Dynavax Technologies were worth $342,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new position in Dynavax Technologies in the 4th quarter worth about $209,000. AlphaMark Advisors LLC bought a new stake in Dynavax Technologies during the fourth quarter valued at approximately $230,000. Duality Advisers LP purchased a new position in Dynavax Technologies in the 1st quarter worth approximately $227,000. Natixis Advisors L.P. increased its holdings in shares of Dynavax Technologies by 10.5% in the 4th quarter. Natixis Advisors L.P. now owns 19,058 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 1,804 shares during the last quarter. Finally, Executive Wealth Management LLC bought a new stake in shares of Dynavax Technologies during the 4th quarter worth $280,000. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Trading Down 1.0 %

Shares of NASDAQ DVAX traded down $0.12 during midday trading on Monday, reaching $11.49. The company had a trading volume of 448,379 shares, compared to its average volume of 2,072,401. The firm’s fifty day moving average price is $11.36 and its 200-day moving average price is $12.03. The company has a quick ratio of 14.10, a current ratio of 15.20 and a debt-to-equity ratio of 0.36. Dynavax Technologies Co. has a one year low of $10.23 and a one year high of $15.15. The stock has a market cap of $1.50 billion, a PE ratio of 193.50 and a beta of 1.28.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). Dynavax Technologies had a net margin of 3.91% and a return on equity of 1.52%. The company had revenue of $50.79 million for the quarter, compared to analysts’ expectations of $51.98 million. On average, equities research analysts anticipate that Dynavax Technologies Co. will post 0.12 earnings per share for the current year.

Analyst Ratings Changes

DVAX has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a research report on Friday, June 28th. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $25.33.

Insider Buying and Selling at Dynavax Technologies

In related news, Director Francis Cano sold 3,615 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $11.93, for a total value of $43,126.95. Following the sale, the director now directly owns 36,905 shares of the company’s stock, valued at $440,276.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.98% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.